These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3540013)

  • 21. Blood group antigens in epithelial tumours of the urinary bladder.
    Marek J; Hradec E; Hanus M; Smolová H
    Czech Med; 1988; 11(3):137-45. PubMed ID: 3147171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell surface antigen in bilharzial bladder tumours.
    Halim A; Javadpour N; Kasraeian A; Young JD
    Br J Urol; 1986 Oct; 58(5):523-5. PubMed ID: 3096417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A, B, O (H) antigenic determinants in superficial transitional cell tumors of bladder.
    Selli C; Cozzolino F; Vercelli D; Mincione GP
    Urology; 1983 Feb; 21(2):132-4. PubMed ID: 6186066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Study of the Thomsen-Friedenreich antigen in bladder tumors].
    Fukatsu H; Yamada H; Nonomura H; Miyagawa Y; Waki M; Hatano Y; Hiraiwa S; Muramatsu T; Nishikawa E; Yamada Y
    Hinyokika Kiyo; 1988 Feb; 34(2):260-7. PubMed ID: 3376818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A, B, H antigen expression in transitional cell carcinomas of the urinary bladder.
    Juhl BR; Hartzen SH; Hainau B
    Cancer; 1986 May; 57(9):1768-75. PubMed ID: 2420436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of DNA ploidy and ABH antigen reactivity in both frozen and formalin-fixed bladder tumor tissue.
    Malmström PU; Vasko J; Wester K; Busch C
    Urol Res; 1991; 19(6):357-9. PubMed ID: 1759329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A, B, H antigen detectability in normal and neoplastic urothelium. Influence of methodologic factors.
    Limas C; Lange P
    Cancer; 1982 Jun; 49(12):2476-84. PubMed ID: 7074564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of monoclonal antibody E48 in diagnosing transitional cell carcinoma of urinary bladder.
    Torenbeek R; Blomjous CE; Quak JJ; Ybema S; Meijer CJ
    J Clin Pathol; 1992 Apr; 45(4):303-7. PubMed ID: 1374431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [CEA and ABO antigens as early signs of malignancy in urotheliomas of the upper urinary tract].
    Cisternino A; Argona F; Garbeglio A; Ranieri A; Bassi P; Pergoraro V
    Arch Esp Urol; 1986 Oct; 39(8):529-33. PubMed ID: 3827317
    [No Abstract]   [Full Text] [Related]  

  • 30. [Specific erythrocyte adherence reaction: an index of the malignant potentials of noninvasive tumors of the human urothelium].
    Anichkov NM; Anichkova SI
    Vopr Onkol; 1980; 26(8):9-13. PubMed ID: 7415061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Immunohistochemical demonstration of carcinoembryonic antigen (CEA) and ABO (H) blood group antigens on tissue sections of urinary bladder tumors].
    Fujioka T; Tanji S; Koike H; Kubo T; Ohhori T
    Hinyokika Kiyo; 1985 Oct; 31(10):1709-16. PubMed ID: 3911765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Expression of the blood group antigens A and B in carcinoma of the urinary bladder].
    Tichý M; Jansa P; Student V; Tichá V; Vanák J
    Bratisl Lek Listy; 1992 Aug; 93(8):415-20. PubMed ID: 1464022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transitional cell carcinoma of the bladder. Differences between primary tumour and following relapses.
    Pizza G; Viza D; Fini M; Cuzzocrea D; Menniti D; Corrado F
    Eur Urol; 1980; 6(1):45-7. PubMed ID: 7353578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A, B, H antigens in transitional cell tumors of the urinary bladder: correlation with the clinical course.
    Limas C; Lange P; Fraley EE; Vessella RL
    Cancer; 1979 Dec; 44(6):2099-107. PubMed ID: 509389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immunohistochemical determination of antigen 19-9 (CA 19-9) in transitional carcinoma of the bladder].
    Casetta G; Cavallini A; Piana P; Squintone L; Vottero M; Tizzani A
    Minerva Urol Nefrol; 1992; 44(3):169-72. PubMed ID: 1492266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prognostic value of the detection of ABO surface antigens by indirect immunofluorescence technic in transitional tumors of the bladder].
    Borella T; Loro M; Dato I; Merlo F; Giudici M
    Minerva Med; 1986 Sep; 77(34-35):1527-32. PubMed ID: 3531921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Determination of surface ABO(H) isoantigens in transitional cell carcinoma of the bladder. Clinicopathological study. (Part 1)].
    Gelabert Mas A; Corominas J; Arango O
    Actas Urol Esp; 1988; 12(3):248-53. PubMed ID: 3177059
    [No Abstract]   [Full Text] [Related]  

  • 38. Blood group ABO and Lewis antigens in bladder tumors: correlation between glycosyltransferase activity and antigen expression.
    Orntoft TF; Wolf H
    APMIS Suppl; 1988; 4():126-33. PubMed ID: 3146987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical evaluation of serum p53 antibodies in patients with upper urinary tract tumors.
    Watanabe J; Nishiyama H; Kawanishi H; Ito M; Kamoto T; Ogawa O
    J Urol; 2005 Jul; 174(1):73-5. PubMed ID: 15947581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ABH secretor status in patients with bladder tumours.
    Paterson PJ
    Urol Res; 1976; 4(4):147-50. PubMed ID: 1020066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.